Host Cytokine Responses Induced after Overnight Stimulation with Novel M. tuberculosis Infection Phase-Dependent Antigens Show Promise as Diagnostic Candidates for TB Disease
Background We previously identified Mycobacterium tuberculosis (M.tb) antigen-induced host markers that showed promise as TB diagnostic candidates in 7-day whole blood culture supernatants. The aim of the present study was to evaluate the utility of these markers further, and cross-compare results with short-term antigen stimulated and unstimulated culture supernatants. Methods We recruited 15 culture confirmed TB cases and 15 non-TB cases from a high-TB endemic community in Cape Town, South Africa into a pilot case-control study from an on-going larger study. Blood samples collected from study participants were stimulated with 4 M.tb antigens that were previously identified as promising (ESAT6/CFP10 (early secreted), Rv2029c (latency), Rv2032 (latency) and Rv2389c (rpf)) in a 7-day or overnight culture assay. Supernatants were also collected form the standard QuantiFERON In Tube (QFT-IT) test. The levels of 26 host markers were evaluated in the three culture supernatants using the Luminex platform. Results The unstimulated levels of CRP, Serum amyloid P (SAP) and serum amyloid A (SAA) and ESAT-6/CFP-10 specific IP-10 and SAA were amongst the best discriminatory markers in all 3 assays, ascertaining TB with AUC of 72–84%. Four-marker models accurately classified up to 92%, 100% and 100% of study participants in the overnight, 7-day and Quantiferon culture supernatants, respectively, after leave-one-out cross validation. Conclusion Unstimulated and antigen-specific levels of CRP, SAA, IP-10, MMP-2 and sCD40L hold promise as diagnostic candidates for TB disease in short-term stimulation assays. Larger studies are required to validate these findings but the data suggest that antigen-specific cytokine production and in particular mutimarker biosignatures might contribute to future diagnostic strategies.
References
[1]
World Health Organization (2012) Global Tuberculosis Report 2012: WHO fact sheet number 104. Available: http://www.who.int/tb/publications/facts？heet_global.pdf.
[2]
Chegou NN, Hoek KGP, Kriel M, Warren RM, Victor TC, et al. (2011) Tuberculosis assays: past, present and future. Expert Rev Anti Infect Ther 4: 457–469. doi: 10.1586/eri.11.23
[3]
Verweij KE, Kamerik AR, Van Ingen J, van Dijk JH, Sikwangala P, et al. (2010) Application of modern microbiological diagnostic methods for tuberculosis in Macha, Zambia. Int. J. Tuberc. Lung Dis 14: 1127–1131.
[4]
Dowdy DW, Louren？o MC, Cavalcante SC, Saraceni V, King B, et al. (2008) Impact and cost-effectiveness of culture for diagnosis of tuberculosis in HIV-infected Brazilian adults,”. PLoS ONE 3: e4057. doi: 10.1371/journal.pone.0004057
[5]
Steingart KR, Sohn H, Schiller I, Kloda LA, Boehme CC, et al. (2013) Xpert MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database of Systematic Reviews 1: CD009593 DOI: 10.1002/14651858.CD009593.
[6]
Kirwan DE, Cárdenas MK, Gilman RH (2012) Rapid Implementation of New TB Diagnostic Tests: Is It Too Soon for a Global Roll-Out of Xpert MTB/RIF? Am. J. Trop. Med. Hyg 87: 197–201. doi: 10.4269/ajtmh.2012.12-0107
[7]
Trébucq A, Enarson DA, Chiang CY, Van Deun A, Harries AD, et al. (2011) Xpert MTB/RIF for national tuberculosis programmes in low-income countries: when, where and how? Int. J. Tuberc. Lung Dis 15: 1567–1572. doi: 10.5588/ijtld.11.0392
[8]
Kashino SS, Pollock N, Napolitano DR, Rodrigues DR, Campos-Neto A (2008) Identification and characterization of Mycobacterium tuberculosis antigens in urine of patients with active pulmonary tuberculosis: an innovative and alternative approach of antigen discovery of useful microbial molecules. Clin. Exp. Immunol. 153 ; 56–62.
[9]
Boehme C, Molokova E, Minja F, Geis S, Loscher T, et al. (2005) Detection of mycobacterial lipoarabinomannan with an antigen-capture ELISA in unprocessed urine of Tanzanian patients with suspected tuberculosis. Trans. R. Soc. Trop. Med. Hyg. 99: 893–900. doi: 10.1016/j.trstmh.2005.04.014
[10]
Sester S, Sotgiu G, Lange C, Giehl C, Girardi E, et al. (2011) Interferon-γ release assays for the diagnosis of active tuberculosis: a systematic review and meta-analysis. Eur. Respir. J. 37: 100–111. doi: 10.1183/09031936.50114810
[11]
Pai M, Menzies D (2007) The new IGRA and the old TST: making good use of disagreement. Am. J. Respir. Crit. Care Med 175: 529–531. doi: 10.1164/rccm.200701-024ed
[12]
Chegou NN, Black GF, Loxton AG, Stanley K, Essone PN, et al. (2012) Potential of novel Mycobacterium tuberculosis infection phase-dependent antigens in the diagnosis of TB disease in a high burden setting. BMC Infect. Dis.12: 10. doi: 10.1186/1471-2334-12-10
[13]
Dosanjh DPS, Bakir M, Millington KA, Soysal A, Aslan Y, et al. (2011) Novel M tuberculosis Antigen-Specific T-Cells Are Early Markers of Infection and Disease Progression. PLoS ONE 6: e28754. doi: 10.1371/journal.pone.0028754
[14]
Chegou NN, Black GF, Kidd M, van Helden PD, Walzl G (2009) Host markers in QuantiFERON supernatants differentiate active TB from latent TB infection: preliminary report,” BMC Pulm Med. 9: 21. doi: 10.1186/1471-2466-9-21
[15]
Chegou NN, Essone PN, Loxton AG, Stanley K, Black GF, et al. (2012) Potential of host markers produced by infection phase-dependent antigen-stimulated cells for the diagnosis of tuberculosis in a highly endemic area. PLoS ONE 7: e38501. doi: 10.1371/journal.pone.0038501
[16]
Franken KL, Hiemstra HS, van Meijgaarden KE, Subronto Y, den Hartigh J, et al. (2000) Purification of his-tagged proteins by immobilized chelate affinity chromatography: the benefits from the use of organic solvent. Protein Expr. Purif. 18: 95–99. doi: 10.1006/prep.1999.1162
[17]
Fluss R, Faraggi D (2005) Reiser B Estimation of the Youden Index and its associated cutoff point. Biom J 47: 458–472. doi: 10.1002/bimj.200410135
[18]
Commandeur S, van Meijgaarden KE, Lin MY, Franken KLMC, Friggen AH, et al. (2011) Identification of Human T-Cell Responses to Mycobacterium tuberculosis Resuscitation-Promoting Factors in Long-Term Latently Infected Individuals. Clin Vaccine Immunol 18: 676–683. doi: 10.1128/cvi.00492-10
[19]
Chegou NN, Detjen AK, Thiart L, Walters E, Mandalakas et al (2013) Utility of Host Markers Detected in Quantiferon Supernatants for the Diagnosis of Tuberculosis in Children in a High-Burden Setting. PLoS ONE 8: e64226. doi: 10.1371/journal.pone.0064226
[20]
Phalane KG, Kriel M, Loxton AG, Menezes A, Stanley K, et al. (2013) Differential expression of host biomarkers in saliva and serum samples from individuals with suspected pulmonary tuberculosis. Mediators Inflamm 2013: 981984. doi: 10.1155/2013/981984
[21]
Noh S, Jung JJ, Jung M, Kim TS, Park CH (2011) MMP-2 as a putative biomarker for carcinomatosis in gastric cancer. Hepatogastroenterology 58: 2015–2019. doi: 10.5754/hge11209
[22]
Safranek J, Pesta M, Holubec L, Kulda V, Dreslerova J (2009) Expression of MMP-7, MMP-9, TIMP-1 and TIMP-2 mRNA in lung tissue of patients with non-small cell lung cancer (NSCLC) and benign pulmonary disease. Anticancer Res. 29: 2513–2517.
[23]
Kanoh Y, Abe T, Masuda N, Akahoshi T (2013) Progression of non-small cell lung cancer: diagnostic and prognostic utility of matrix metalloproteinase-2, C-reactive protein and serum amyloid A. Oncol. Rep. 29: 469–473. doi: 10.3892/or.2012.2123
[24]
Fujiwara H, Suchi K, Okamura S, Okamura H, Umehara S (2011) Elevated serum CRP levels after induction chemoradiotherapy reflect poor treatment response in association with IL-6 in serum and local tumor site in patients with advanced esophageal cancer. J Surg Oncol 103: 62–68. doi: 10.1002/jso.21751
[25]
dos Anjos BL, Grotto HZW (2010) Evaluation of C-reactive protein and serum amyloid A in the detection of inflammatory and infectious diseases in children. Clin. Chem. Lab. Med. 48: 493–499. doi: 10.1515/cclm.2010.110
[26]
Maasilta P, Kostiala AA (1989) Serum levels of C-reactive protein in patients with pulmonary tuberculosis and malignant tumors of the chest. Infection 17: 13–14. doi: 10.1007/bf01643491
[27]
Wayne LG, Sohaskey CD (2001) Nonreplicating persistence of mycobacterium tuberculosis. Annu. Rev. Microbiol. 55: 139–163. doi: 10.1146/annurev.micro.55.1.139
[28]
Lin MY, Ottenhoff THM (2008) Not to wake a sleeping giant: new insights into host-pathogen interactions identify new targets for vaccination against latent Mycobacterium tuberculosis infection. Biol. Chem.389: 497–511. doi: 10.1515/bc.2008.057
[29]
Wu X, Yang Y, Han Y, Zhang J, Liang Y (2008) Effect of recombinant Rv1009 protein on promoting the growth of Mycobacterium tuberculosis. J. Appl. Microbiol. 105: 1121–1127. doi: 10.1111/j.1365-2672.2008.03850.x
[30]
Ria？o F, Arroyo L, París S, Rojas M, Friggen AH (2012) T cell responses to DosR and Rpf proteins in actively and latently infected individuals from Colombia. Tuberculosis. 92: 148–159. doi: 10.1016/j.tube.2011.12.005
Kaufmann SHE, Parida SK (2008) Tuberculosis in Africa: learning from pathogenesis for biomarker identification. Cell Host Microbe 4: 219–228. doi: 10.1016/j.chom.2008.08.002
[33]
Black GF, Thiel BA, Ota MO, Parida SK, Adegbola R (2009) Immunogenicity of novel DosR regulon-encoded candidate antigens of Mycobacterium tuberculosis in three high-burden populations in Africa. Clin. Vaccine Immunol. 16: 1203–1212. doi: 10.1128/cvi.00111-09
[34]
World Health Organization (2011) Use of tuberculosis interferon - gamma release assays (IGRAs) in low - and middle - income countries: policy statement.
[35]
Corstjens PLAM, Chen Z, Zuiderwijk M, Bau HH, Abrams WR, et al. (2007) Rapid assay format for multiplex detection of humoral immune responses to infectious disease pathogens (HIV, HCV, and TB). Ann. N. Y. Acad. Sci. 1098: 437–445. doi: 10.1196/annals.1384.016
[36]
Corstjens PLAM, van Lieshout l, Zuiderwijk M, Kornelis D, Tanke HJ, et al. (2008) Up-converting phosphor technology-based lateral flow assay for detection of Schistosoma circulating anodic antigen in serum. J. Clin. Microbiol. 46: 171–176. doi: 10.1128/jcm.00877-07
